Form 4: Director Steven Rubin Acquires Niagen Bioscience Stock Options

Director Steven D. Rubin acquired stock options for 31,746 shares of Niagen Bioscience, Inc. (NAGE) on June 24, 2026.

Summary

• Steven D. Rubin, a Director at Niagen Bioscience, Inc., acquired stock options on June 24, 2026.
• The transaction involved 31,746 stock options with an exercise price of $3.45 per share.
• These options are exercisable starting June 24, 2027, and expire on June 23, 2036.
• The underlying securities are 31,746 shares of Common Stock.
• The options are held directly by Mr. Rubin.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider option grants can be positive, this is a routine disclosure of compensation and not a direct investment of personal capital, and the value is contingent on future performance.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of a significant number of options (31,746) by a director may indicate a belief in potential stock appreciation.

Negatives

• This filing is a routine Form 4 reporting an option grant, not a purchase of stock with cash, so it doesn't represent an immediate cash investment by the director.
• The options are not immediately exercisable, with a vesting date in June 2027.

Risks

• The value of the stock options is subject to market fluctuations and the company's performance.
• If the stock price does not exceed the exercise price of $3.45, the options may expire worthless.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The future outlook for the stock options depends on the company's performance and stock price appreciation.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Niagen Bioscience, Inc., are standard disclosures for insider transactions. The acquisition of stock options by a director is a common practice to align management's interests with shareholders, but the actual value realized depends entirely on future stock performance.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially incentivizing performance. However, the immediate impact is minimal as it's not a cash purchase.
• Employees: May view this as a positive sign of director commitment, but it does not directly affect employee compensation or roles.
• Management: Reinforces the standard compensation structure for directors.

Next Steps

• The stock options will vest on June 24, 2027.
• The options can be exercised anytime between June 24, 2027, and June 23, 2036, provided the stock price is above the $3.45 exercise price.

Key Dates

Keywords

Form 4, Stock Options, Insider Trading, Niagen Bioscience, NAGE, Director, Beneficial Ownership, Securities Exchange Act